B72:FRA
AtaiBeckley Inc
€4.34
arrow_upward
+0.46%(+0.020) 1 日
7月6日, 8:08:57 GMT+2 · EUR
search
すべての記号
1 日
5 日
1 か月
6 か月
年初来
1 年
5 年
最大
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_autoB72 の上位の分析情報を生成しています...
始値
€4.34
高値
€4.34
安値
€4.34
時価総額
19.11億
平均出来高
1891.00
取引量
0.00
52 週高値
€5.30
52 週安値
€2.70
従業員数
99
始値
€4.34
高値
€4.34
安値
€4.34
時価総額
19.11億
平均出来高
1891.00
取引量
0.00
52 週高値
€5.30
52 週安値
€2.70
従業員数
99
ニュース記事
ウェブの情報から
Yahoo! Finance Canada
·
39 分前
AtaiBeckley completes dosing in Phase 2b depression trial, expects topline data in Q4
Investing.com
·
1 時間前
AtaiBeckley completes dosing in VLS-01 depression trial
プロフィール
AtaiBeckley Inc. is a clinical-stage biotechnology company developing treatments for mental health disorders, including therapies based on psychedelics, entactogens, and related compounds. The company was founded in November 2025 through the combination of atai Life Sciences N.V. and Beckley Psytech Limited. atai Life Sciences was founded in 2018 and became a publicly listed company in 2021. Beckley Psytech, a private company, was founded in 2019. In December 2025, the combined company redomiciled from the Netherlands to the U.S., incorporated in Delaware and headquartered in New York, NY. The company's shares trade on the Nasdaq stock exchange under the ticker symbol ATAI.
The company's pharmaceutical candidates include mebufotenin for treatment-resistant depression, dimethyltryptamine for treatment-resistant depression, and-midomafetamine for social anxiety disorder. The company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and treatment-resistant depression. Wikipedia
AtaiBeckley Inc について